ArticleCardiovascular and interventional radiology2026
Safety and Efficacy of Irreversible Electroporation in the Treatment of Lesions Near or Involving Gastrointestinal Structures.
Article in Cardiovascular and interventional radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the safety and local efficacy of irreversible electroporation (IRE) for soft tissue lesions near or involving gastrointestinal structures. MATERIAL AND
methodsThis single-center retrospective study analyzed patients treated with percutaneous IRE for lesions near or involving gastrointestinal structures from June 2018 to March 2024. Safety was assessed by complications graded according to CTCAE criteria. Efficacy, a secondary outcome, was evaluated based on tumor response and local progression-free survival (LPFS) using mRECIST and PERCIST criteria. Additional secondary outcomes included length of hospital stay.
resultsTwenty-five patients underwent IRE for 30 lesions near the stomach, small bowel, colon, or rectum. Primary cancers included pancreatic (n = 1), uterine (n = 1), urothelial (n = 2), prostate (n = 2), small intestine (n = 3), renal cell (n = 4) and colorectal (n = 12). Median age was 65 years, mean lesion size 2.4 cm, and technical success 100%. Complications occurred in 34.8% (all grade 1), with no gastrointestinal perforations. Median hospital stay was 1 night. Median follow-up was 25.3 months; LPFS was 24.4 months, with 1- and 2 year rates of 62.0% and 54.3%. In the colorectal cancer subgroup, LPFS was 23.8 months, with 1- and 2 year rates of 58.7% and 47.0%, and median OS 56.1 months (1 year: 100%, 2 year: 87.5%).
conclusionIRE is found to be safe and an effective local treatment for soft tissue metastases near the gastrointestinal tract, offering promising control with minimal complications in challenging anatomical locations. Level of Evidence 4 (retrospective study without a control group).
Indexed as
Identifiers
41145767What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.